After signing up, you'll start to receive regular news updates from us.
Varian Launches Improved OnSite® OraLab® Device
Complete the form below to unlock access to ALL audio articles.
Varian, Inc. has announced an improved version of the OnSite® OraLab® oral fluid drug testing device.
Featuring a proprietary detection methodology, the OraLab is designed to achieve lower detection limits for parent-THC than previous devices.
OraLab is an extension of Varian, Inc.'s drugs of abuse oral fluid testing product line that offers devices for both onsite and lab-based testing.
OraLab's testing process is 100% observable and eliminates the need for special facilities or gender-specific staffing, which makes specimen tampering less likely.
The OraLab's patent-pending expresser and single tube design allows collection and storage of sufficient saliva for both immediate screening and confirmation testing.
OraLab is used for pre-employment, random, reasonable suspicion, and post-accident testing, as well as for court-mandated compliance.
OraLab simultaneously screens for six drugs - amphetamine, opiates, cocaine, PCP, methamphetamine, and THC.
It is also available in a three-drug test panel for amphetamine, opiates, and cocaine.
"There continues to be growing interest in oral fluid testing because of the many benefits of oral fluid collection over urine collection," said Stephen Schultheis, Consumable Products Vice President and General Manager, Varian, Inc.
"The new and improved OraLab not only offers our customers more sensitive and more accurate detection of parent-THC, it's also easier to use. With three easy steps - collect, test, and store - test results are ready in minutes."
"If a customer wants to detect "under the influence" drug use, oral fluid testing is the ideal choice."
